- NorthStar opens new manufacturing center in Beloit, Wisconsin, aimed at enhancing radiopharmaceutical production for therapeutic and diagnostic applications.
- The facility will focus on meeting growing demand for radioisotopes used in cancer treatment and medical imaging.
NorthStar Medical Radioisotopes, a radiopharmaceutical Contract Development and Manufacturing Organization, officially opened its new Dose Manufacturing Center in Beloit, Wisconsin. The state-of-the-art facility will increase NorthStar’s capacity to support biopharmaceutical companies in the development and production of critical radioisotopes used for therapeutic and diagnostic purposes. The event was marked by a ribbon-cutting ceremony and featured speakers from key industry leaders, including Dr. Philip Kantoff, CEO of Convergent Therapeutics, and Shaemus Gleason, Executive Vice President of Clarity Pharmaceuticals.
The new facility will provide customized solutions for pharmaceutical companies, addressing the growing demand for radioisotopes and the complexities of their development and manufacturing. It is designed to support the entire pharmaceutical lifecycle, from early research and clinical trials through to commercial production, with a focus on advanced radioisotopes such as Actinium-225 (Ac-225) and Copper-67 (Cu-67), which are being explored in cancer therapies.
Frank Scholz, President and CEO of NorthStar, said, “NorthStar has evolved into a company capable of developing, producing, and delivering a broad range of pharmaceuticals from one integrated campus. Our facility is purpose-built for scalability, reliability, and safety, which enables us to meet the increasing needs of our customers.”
The new facility will help expand NorthStar’s role in the supply chain for biopharmaceutical companies. It will address the specialized requirements for the development of radiopharmaceuticals, especially for companies without in-house capabilities. Scholz added that the facility is already producing Cu-67 and will begin producing Ac-225 later this year.
Read about the Radiopharmaceutical CDMO Market here.
Overview of outsourcing trends 
